The modified vaccinia Ankara-Bavarian Nordic mpox vaccine (MVA-BN; Jynneos) generated robust immune responses in adolescents ...

ProBioGen’s AGE1.CR.PIX been developed as a stable proliferating avian cell line that is highly permissive for different ...

New data show tolerability and no evidence of spreading to blood or tissues even at high doses of Tonix’s attenuated ...

The Phase II trial seeks to further validate the potential of Olvi-Vec in resensitising patients to platinum therapies across ...

Guggenheim last night initiated coverage of Genelux (GNLX) with a Buy rating and $8 price target Genelux is a clinical-stage Biotech company ...

Chatham, New Jersey Wednesday, November 6, 2024, 18:00 Hrs [IST] ...

Pexa-Vec (pexastimogene devacirepvec) is a modified vaccinia virus that has been engineered to express immune-boosting cytokine GM-CSF. The PHOCUS trial of Pexa-Vec was terminated on the advice of ...

About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary ...

The MVA-MERS-S vaccine candidate developed at the German Center for Infection Research (DZIF) since 2013 is based on an attenuated virus—the so-called "Modified Vaccinia Ankara Virus" (MVA ...

KaliVir is at the forefront of developing novel cancer therapies using its proprietary Vaccinia Enhanced Template (VET™) platform. This platform allows for the expression and systemic delivery ...

The Foreign, Commonwealth and Development Office (FCDO) shared the latest health information for the European Union country.